Abstract
This study further expands our previous observation demonstrating the usefulness of combination therapy of anti-TNF-alpha and cyclosporine A in the treatment of rheumatoid arthritis and concurrent hepatitis C virus infection, as well its efficacy and safety in controlling HCV viremia and liver toxicity. Seven patients were included in the study; transaminase levels remained unchanged, HCV RNA serum levels decreased significantly and DAS 28 significantly improved after twelve month follow-up. No side effects were registered.
MeSH terms
-
Adalimumab
-
Adult
-
Aged
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Antiviral Agents / adverse effects
-
Antiviral Agents / therapeutic use*
-
Arthritis, Rheumatoid / complications
-
Arthritis, Rheumatoid / drug therapy*
-
Arthritis, Rheumatoid / immunology
-
Cyclosporine / adverse effects
-
Cyclosporine / therapeutic use*
-
Drug Therapy, Combination
-
Etanercept
-
Female
-
Hepacivirus / genetics
-
Hepatitis C, Chronic / complications
-
Hepatitis C, Chronic / diagnosis
-
Hepatitis C, Chronic / drug therapy*
-
Hepatitis C, Chronic / immunology
-
Humans
-
Immunoglobulin G / adverse effects
-
Immunoglobulin G / therapeutic use
-
Immunosuppressive Agents / adverse effects
-
Immunosuppressive Agents / therapeutic use*
-
Italy
-
Male
-
Middle Aged
-
Pilot Projects
-
Prospective Studies
-
RNA, Viral / blood
-
Receptors, Tumor Necrosis Factor / therapeutic use
-
Severity of Illness Index
-
Time Factors
-
Treatment Outcome
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
-
Viral Load
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antiviral Agents
-
Immunoglobulin G
-
Immunosuppressive Agents
-
RNA, Viral
-
Receptors, Tumor Necrosis Factor
-
Tumor Necrosis Factor-alpha
-
Cyclosporine
-
Adalimumab
-
Etanercept